Brevan Howard Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Brevan Howard Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,238	Closed	-$226K	–	2144
2025 Q4	$226K	Sell	1,238 -6,096	-83%	-$851K	﹤0.01%	1520
2025 Q3	$891K	Sell	7,334 -7,448	-50%	-$839K	﹤0.01%	958
2025 Q2	$1.54M	Buy	+14,782	New	+$1.57M	0.01%	853
2025 Q1	–	Sell	-38,748	Closed	-$3.28M	–	1163
2024 Q4	$3.28M	Buy	38,748 +24,393	+170%	+$2.24M	0.02%	200
2024 Q3	$1.29M	Buy	14,355 +9,573	+200%	+$836K	0.01%	376
2024 Q2	$385K	Buy	+4,782	New	+$354K	﹤0.01%	694

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's AXSM Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,238 shares — an estimated $226K sold.

Brevan Howard Capital Management first reported a position in AXSM in Q2 2024 and held it in 6 quarters. The position peaked at $3.28M in Q4 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Brevan Howard Capital Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 1,238 Axsome Therapeutics shares in Q1 2026, an estimated $226K.
Brevan Howard Capital Management first reported a position in Axsome Therapeutics in Q2 2024 and held it in 6 quarters.
Brevan Howard Capital Management's Axsome Therapeutics position peaked at $3.28M in Q4 2024.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.